[
  {
    "ts": null,
    "headline": "Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=f4b338aab3db2af08d143deb949cb411872bfc0be2748a0e9947708132e38f34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754607603,
      "headline": "Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136266935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=f4b338aab3db2af08d143deb949cb411872bfc0be2748a0e9947708132e38f34"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates",
    "summary": "Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=6f1612831c0d073360e4c03c7c4cf507f33b8508d9c4e71802542d16944ca7bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754602801,
      "headline": "Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates",
      "id": 136266936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=6f1612831c0d073360e4c03c7c4cf507f33b8508d9c4e71802542d16944ca7bd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript",
    "summary": "Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript",
    "url": "https://finnhub.io/api/news?id=f9fb85f5a812a61481d8470fe3935ae395522dd69179c6df6c9939111e64b82f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754602749,
      "headline": "Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript",
      "id": 136263735,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f9fb85f5a812a61481d8470fe3935ae395522dd69179c6df6c9939111e64b82f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot",
    "summary": "Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the company’s broader business.",
    "url": "https://finnhub.io/api/news?id=be0293f3c5e212600219c73db37b82384b426b5aeb41bc9404ebac0509131114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754601180,
      "headline": "Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot",
      "id": 136266937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the company’s broader business.",
      "url": "https://finnhub.io/api/news?id=be0293f3c5e212600219c73db37b82384b426b5aeb41bc9404ebac0509131114"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Raises Guidance After Results Top Views",
    "summary": "The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and Livdelzi.",
    "url": "https://finnhub.io/api/news?id=7d5fff463201c24d7b20e5aede00a177c715006a3419abf0d5c731b7e4659511",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754600760,
      "headline": "Gilead Sciences Raises Guidance After Results Top Views",
      "id": 136266938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and Livdelzi.",
      "url": "https://finnhub.io/api/news?id=7d5fff463201c24d7b20e5aede00a177c715006a3419abf0d5c731b7e4659511"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NASDAQ:GILD) Beats Q2 Sales Targets",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=7ffbc62825ce48944b6057c6868bd6e61ba6f42ef4575bd1ba46934e71e4909a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754599462,
      "headline": "Gilead Sciences (NASDAQ:GILD) Beats Q2 Sales Targets",
      "id": 136266939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=7ffbc62825ce48944b6057c6868bd6e61ba6f42ef4575bd1ba46934e71e4909a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences earnings top estimates, boosts full-year outlook",
    "summary": "Gilead Sciences (GILD) posted second quarter results that topped Wall Street estimates on both the top and bottom lines. The company also raised its full-year earnings guidance. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=6eb8cbdd42f01ad3a9030e952c9b1393fe4aebdb2273858d629e288914f6ae49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754599189,
      "headline": "Gilead Sciences earnings top estimates, boosts full-year outlook",
      "id": 136266940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) posted second quarter results that topped Wall Street estimates on both the top and bottom lines. The company also raised its full-year earnings guidance. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=6eb8cbdd42f01ad3a9030e952c9b1393fe4aebdb2273858d629e288914f6ae49"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: Q2 Earnings Snapshot",
    "summary": "GILD) on Thursday reported second-quarter net income of $1.96 billion. On a per-share basis, the Foster City, California-based company said it had net income of $1.56. Earnings, adjusted for one-time gains and costs, came to $2.01 per share.",
    "url": "https://finnhub.io/api/news?id=48fa7b36d4030a4d15deeadb6bc7cd8029565fd02a2da1a03de096cbec307131",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754598936,
      "headline": "Gilead: Q2 Earnings Snapshot",
      "id": 136266941,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD) on Thursday reported second-quarter net income of $1.96 billion. On a per-share basis, the Foster City, California-based company said it had net income of $1.56. Earnings, adjusted for one-time gains and costs, came to $2.01 per share.",
      "url": "https://finnhub.io/api/news?id=48fa7b36d4030a4d15deeadb6bc7cd8029565fd02a2da1a03de096cbec307131"
    }
  },
  {
    "ts": null,
    "headline": "Gilead posts flat second quarter profit, ups full-year outlook on strong HIV sales",
    "summary": "(Reuters) -Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.  Shares of the California-based biotech company, which closed at $100.28 in regular Nasdaq trading, were up nearly 3% at $113.28 after hours.  Gilead's adjusted earnings per share were flat from a year earlier at $2.01, and just ahead of the average of analysts' estimates of $1.97, as compiled by LSEG.",
    "url": "https://finnhub.io/api/news?id=9d515fdfe6db0875cbdbe215d43aacb199ee75e5e417d9e21fd5f5f5138bf1ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754598305,
      "headline": "Gilead posts flat second quarter profit, ups full-year outlook on strong HIV sales",
      "id": 136266942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "(Reuters) -Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.  Shares of the California-based biotech company, which closed at $100.28 in regular Nasdaq trading, were up nearly 3% at $113.28 after hours.  Gilead's adjusted earnings per share were flat from a year earlier at $2.01, and just ahead of the average of analysts' estimates of $1.97, as compiled by LSEG.",
      "url": "https://finnhub.io/api/news?id=9d515fdfe6db0875cbdbe215d43aacb199ee75e5e417d9e21fd5f5f5138bf1ac"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announces Second Quarter 2025 Financial Results",
    "summary": "FOSTER CITY, Calif., August 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations.",
    "url": "https://finnhub.io/api/news?id=bad5aecc4b75963b81caee13d36ddf55e3877a881092e9144a935b9a287ee30e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754596920,
      "headline": "Gilead Sciences Announces Second Quarter 2025 Financial Results",
      "id": 136266943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., August 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations.",
      "url": "https://finnhub.io/api/news?id=bad5aecc4b75963b81caee13d36ddf55e3877a881092e9144a935b9a287ee30e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Q2: The New Drug That Could Change Everything",
    "summary": "Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its nice valuation and promising pipeline.",
    "url": "https://finnhub.io/api/news?id=663e0357ddbf9d03354a1f959d293430557b0afc75e3367a495a4d8c47743627",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754594796,
      "headline": "Gilead Sciences Q2: The New Drug That Could Change Everything",
      "id": 136262971,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its nice valuation and promising pipeline.",
      "url": "https://finnhub.io/api/news?id=663e0357ddbf9d03354a1f959d293430557b0afc75e3367a495a4d8c47743627"
    }
  },
  {
    "ts": null,
    "headline": "How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly earnings at $1.96 per share, down from $2.01 per share in the year-ago period. Gilead Sciences projects to report quarterly revenue of $6.96 billion, compared to $6.95 billion a year earlier, according to data from Benzinga Pro. On July 25, Needham analyst Joseph Stringer upgraded Gilead Sciences from Hol",
    "url": "https://finnhub.io/api/news?id=df137942d7e56b3c52a29547e7f6b7fb1ec98d0c13c721aadccb836c491e959e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754592689,
      "headline": "How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings",
      "id": 136266944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly earnings at $1.96 per share, down from $2.01 per share in the year-ago period. Gilead Sciences projects to report quarterly revenue of $6.96 billion, compared to $6.95 billion a year earlier, according to data from Benzinga Pro. On July 25, Needham analyst Joseph Stringer upgraded Gilead Sciences from Hol",
      "url": "https://finnhub.io/api/news?id=df137942d7e56b3c52a29547e7f6b7fb1ec98d0c13c721aadccb836c491e959e"
    }
  },
  {
    "ts": null,
    "headline": "Equities Fall Intraday as Markets Weigh Earnings",
    "summary": "US benchmark equity indexes were lower intraday as traders assessed the latest corporate earnings.",
    "url": "https://finnhub.io/api/news?id=b925e3e78d6dcd2f7b3bc2f7ba9f154563df96f22646531fed5588370faf7603",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754590470,
      "headline": "Equities Fall Intraday as Markets Weigh Earnings",
      "id": 136266945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were lower intraday as traders assessed the latest corporate earnings.",
      "url": "https://finnhub.io/api/news?id=b925e3e78d6dcd2f7b3bc2f7ba9f154563df96f22646531fed5588370faf7603"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Earnings Beat Estimates, But All Eyes Are on a New HIV Shot",
    "summary": "Gilead Earnings Beat Estimates, But All Eyes Are on a New HIV Shot",
    "url": "https://finnhub.io/api/news?id=493aca60b22bf79ee5a11640369215d33a8f5076fff767582baab26d9ea6ebfe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754586780,
      "headline": "Gilead Earnings Beat Estimates, But All Eyes Are on a New HIV Shot",
      "id": 136298249,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Earnings Beat Estimates, But All Eyes Are on a New HIV Shot",
      "url": "https://finnhub.io/api/news?id=493aca60b22bf79ee5a11640369215d33a8f5076fff767582baab26d9ea6ebfe"
    }
  },
  {
    "ts": null,
    "headline": "NY Fed delivers harsh inflation surprise",
    "summary": "The market is watching for the latest jobless claims data after the president made a harsh move with a key BLS role.",
    "url": "https://finnhub.io/api/news?id=f54d5fad5bca1b1688ffee2e0457539d2bb4088a3517da0b79efc3365d6ba2ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754576760,
      "headline": "NY Fed delivers harsh inflation surprise",
      "id": 136266946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The market is watching for the latest jobless claims data after the president made a harsh move with a key BLS role.",
      "url": "https://finnhub.io/api/news?id=f54d5fad5bca1b1688ffee2e0457539d2bb4088a3517da0b79efc3365d6ba2ce"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan",
    "summary": "US equity markets were tracking in the green before the opening bell Thursday as President Donald Tr",
    "url": "https://finnhub.io/api/news?id=ab335e9f5c45df39939e76712e8890b1230f6bde44a9b14e64cd9b19ed800538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754567197,
      "headline": "Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan",
      "id": 136245984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US equity markets were tracking in the green before the opening bell Thursday as President Donald Tr",
      "url": "https://finnhub.io/api/news?id=ab335e9f5c45df39939e76712e8890b1230f6bde44a9b14e64cd9b19ed800538"
    }
  }
]